News & Updates
Filter by Specialty:

QoL preserved in patients with refractory mCRC treated with add-on bevacizumab
In the treatment of refractory metastatic colorectal cancer (mCRC), the addition of bevacizumab to trifluridine/tipiracil (FTD/TPI) does not appear to hurt the quality of life (QoL), with patients receiving add-on bevacizumab being able to maintain their QoL for a longer period than those receiving FTD/TPI monotherapy, according to a post hoc analysis of the phase III SUNLIGHT trial.
QoL preserved in patients with refractory mCRC treated with add-on bevacizumab
26 Aug 2023
HCM tied to heart failure in women, all-cause death in men
Hypertrophic cardiomyopathy (HCM) is more common among men in Singapore, reports a study. Women with HCM are more likely to develop heart failure, while men tend to have a worse prognosis in terms of all-cause mortality.
HCM tied to heart failure in women, all-cause death in men
25 Aug 2023
Older age at first screening colonoscopy linked to higher risk of adenomas, CRC
At a first screening colonoscopy, older patients are more likely to have a detection of adenomatous polyps and colorectal cancer (CRC), reveals a study.
Older age at first screening colonoscopy linked to higher risk of adenomas, CRC
25 Aug 2023
Add-on esketamine beneficial to patients with fluctuating antidepressant response
A single dose of esketamine appears to enhance the efficacy of oral antidepressants for treating patients with major depressive disorder (MDD) who are experiencing fluctuating symptoms, as reported in a small study.